Starpharma today announced encouraging results from studies applying its Priostar^® dendrimer technology to the improvement of globally significant agrochemicals.

• Starpharma’s Priostar^® dendrimer found to improve the effectiveness of agrochemicals including glyphosate, the most commonly used herbicide globally;
• Starpharma’s internal development program is focused on the improvement of several existing agrochemicals;
• New patent filing to extend coverage to 2029.

The Age Journalist David Potts notes the resilience of biotech companies in volatile market conditions:  ‘They might not make any money but, hey, that has never stopped a boom. Many biotech stocks have been surging in this sluggish sharemarket.’

Go to the article (external link)

Herald Sun Journalist John Beveridge looks at the diverse, long term investment potential within Starpharma’s research portfolio: ‘Everybody loves to grab a bargain, but when you are aiming to make money, buying a share that is rising is a much better idea than having a constant anxiety attack about paying more than the last buyer.’

Go to the article (external link)

Australian Life Scientist Journalist Tim Dean investigates Starpharma’s pre-clinical studies on popular chemotherapy drug, docataxel:  ‘Chemotherapy drugs are big business, and Melbourne-based Starpharma is looking to get involved by applying its dendrimer technology to reformulate and improve leading therapies.’

Starpharma today announced the nomination of leading anti-cancer drug docetaxel as a lead candidate in its cancer drug delivery program following encouraging early results.

• Starpharma’s dendrimers demonstrate improvements in multibillion dollar chemotherapy drug, docetaxel;
• Water solubility improved more than 2000-fold, potentially reducing serious side effects;
• Starpharma to advance a dendrimer-docetaxel formulation as a lead candidate in its drug delivery cancer program.

Starpharma invites you to listen to an audio broadcast with Chief Executive Officer Dr Jackie Fairley, regarding the successful results of the major phase 2 clinical study that demonstrated efficacy of VivaGel^® for the treatment of bacterial vaginosis (BV).

To listen to the Boardroom Radio audio broadcast please click here. 

Starpharma today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel^® for the treatment of bacterial vaginosis (BV).

 Key Points:

•  VivaGel^® meets primary endpoint, demonstrating significant efficacy for treatment of BV
• VivaGel^® expected to avoid many shortcomings of existing therapies

Starpharma today announced that it has signed a licence agreement with Okamoto Industries Inc  in relation to the VivaGel^®-coated condom for the Japanese market.  Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.

The cash balance at 31 March 2011 was $20.1m compared to $19.7m at 31 December 2010.

The Operating & Investing cash outflow of $1.6m for the quarter includes the costs of the fully enrolled phase 2 study assessing VivaGel^® as a treatment for bacterial vaginosis. Financing cash inflows of $2.0m included proceeds from the exercise of share options during the quarter.